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Abstract: In the upcoming years, the proportion of elderly patients with chronic obstructive 
pulmonary disease (COPD) will increase, according to the progressively aging population and 
the increased efficacy of the pharmacological treatments, especially considering the management 
of chronic comorbidities. The issue to prescribe an appropriate inhalation therapy to COPD 
patients with significant handling or coordination difficulties represents a common clinical 
experience; in the latter case, the choice of an inadequate inhalation device may jeopardize 
the adherence to the treatment and eventually lead to its ineffectiveness. Treatment options 
that do not require particular timing for coordination between activation and/or inhalation 
or require high flow thresholds to be activated should represent the best treatment option for 
these patients. Nebulized bronchodilators, usually used only in acute conditions such as COPD 
exacerbations, could fulfill this gap, enabling an adequate drug administration during tidal 
breathing and without the need for patients’ cooperation. However, so far, only short-acting 
muscarinic antagonists have been available for nebulization. Recently, a nebulized formula-
tion of the inhaled long-acting muscarinic antagonist glycopyrrolate, delivered by means of a 
novel proprietary vibrating mesh nebulizer closed system (SUN-101/eFlow®), has progressed to 
Phase III trials and is currently in late-stage development as an option for maintenance treatment 
in COPD. The present critical review describes the current knowledge about the novel nebulizer 
technology, the efficacy, safety, and critical role of nebulized glycopyrrolate in patients with 
COPD. To this end, PubMed, ClinicalTrials.gov, Embase, and Cochrane Library have been 
searched for relevant papers. According to the available results, the efficacy and tolerability 
profile of nebulized glycopyrrolate may represent a valuable and dynamic treatment option for 
the chronic pharmacological management of patients with COPD.
Keywords: glycopyrrolate, glycopyrronium, nebulizer, COPD, antimuscarinic, device
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by not fully 
reversible airflow obstruction due to structural derangement of the airways, sustained 
by an inflammatory response secondary to inhalation of noxious particles, mainly 
represented by cigarette smoke and air pollutants.1 COPD represents an increasing 
social and health care problem, and a leading cause of disability. In current pro-
jections, mortality due to COPD will eventually increase by 2030 to become the 
third most common cause of death worldwide.2 In COPD, both chronic bronchitis 
and emphysema can be present with different intensities and are responsible for 
airway narrowing, mucus hyper-secretion, loss of small conducting airways, and 
lung elastic recoil.3 Starting from the peripheral airways, which represent the site 
of the initial damage, these anatomic changes eventually lead to expiratory airflow 
limitation, air trapping, dynamic hyperinflation, increased closing volume, and 
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ventilation–perfusion mismatch.4–6 Long-acting muscarinic 
antagonists (LAMAs), such as tiotropium, aclidinium, 
glycopyrronium, and umeclidinium, and long-acting β2 
agonists (LABAs), such as indacaterol, formoterol, sal-
meterol, and olodaterol, are able to reduce hyperinflation7 
and the extent of airway closure,8 improving symptoms 
and exercise tolerance,9 and thus represent the cornerstone 
of the long-term pharmacological treatment in COPD. 
Although inhaled therapy has the advantage to be admin-
istered directly to the site of action, the process interposed 
between the actuation of the device and the drug deposition 
in lung periphery relies on numerous variables, namely the 
drug formulation, patients’ inhalation technique, and lung 
mechanics.10 So far, the most widespread hand-held inhal-
ers’ devices are represented by dry powder inhalers (DPIs), 
pressurized metered dose inhalers (pMDIs), and soft mist 
inhalers (SMIs), while nebulizers are often left for the treat-
ment of acute conditions such as COPD exacerbations or in 
patients with extremely limited self-sufficiency.11 Although 
effective, technologically advanced and portable, the use of 
handheld devices has always been affected by numerous 
major mistakes that lead to an incorrect inhalation technique 
and eventually to the lack of treatment efficacy,10 especially 
in older patients with COPD, with a severe disease and 
multiple comorbidities.10 In the latter group of patients, 
drug delivery via nebulization may provide an effective 
alternative, since an optimal dose can be delivered during 
tidal breathing, regardless of disease severity or associated 
comorbidities, thus overcoming the need for coordination, 
specific handling and inspiratory maneuvers.12
The present critical review will be focused on the nebu-
lized delivery technology, developmental phases, efficacy 
and safety of nebulized glycopyrrolate (nebulized glycopy-
rronium bromide [GBn]) in patients with COPD. Medline, 
Embase, Cochrane Library, and ClinicalTrials.gov were 
searched for relevant full papers and conference abstracts 
up to August 2017. Only manuscripts in English language 
were considered.
Management issues in COPD 
treatment
The peculiarity of the pharmacology of the respiratory system 
is represented by the possibility to grant drug delivery directly 
to the desired site of action, allowing to bypass the majority of 
the intermediate metabolic steps usually inevitable for other 
administration routes.13,14 However, the efficacious access to 
the lung is jeopardized by complex variables that range from 
drug formulation and posology to the pathophysiology and 
stage of the disease. In this view, adherence becomes crucial 
for treatment efficacy. In clinical trials, adherence to inhaled 
treatments is usually .80%,15 a result that does not usually 
reflect the real life context, in which adherence can be as 
low as 10%.16,17 Reduced adherence does not only impact 
the daily clinical management of patients with COPD but 
also increases the frequency of exacerbations, the number 
of hospitalizations, and emergency department visits, thus 
negatively affecting health care costs.18
The device used to deliver the inhaled drug represents a 
fundamental step for the clinical decision process and may 
be as important as the choice of the drug itself. The inhala-
tion devices more commonly prescribed are represented by 
pMDIs, DPIs, SMIs, and nebulizers. Despite a long-standing 
debate, there is no consensus on how to match patient 
requirements with criteria for selecting an alternative inhaler 
device. Rather than insisting with training a patient with 
a specific inhaler, it would be more appropriate to match 
the device with the needs and the skills of the patient.10 
Most of the inhalation devices currently available on the 
market have a comparable efficacy, provided they are used 
appropriately.11,19–21 During drug administration, up to 75% 
of patients with COPD do not receive an optimal dose of 
the inhaled drug, mainly because of poor coordination or 
inhalation techniques.22,23
For pMDIs, the most common administration errors are 
represented by the patient’s poor coordination between the 
device activation and drug inhalation or by a short inhalation 
time. During DPIs’ use, patients are often unable to obtain a 
sufficient inspiratory peak flow necessary get the resistance 
required to activate the drug and dissociate the carrier from 
the active molecule; moreover, common mistakes regard 
dose preparation and exhalation through the device prior to 
inhalation.24–27 Even the use of SMI requires an accurate prim-
ing and breathing technique,28 although the timing for inspira-
tion and the required inspiratory flow are respectively longer 
and lower compared to pMDIs, since the delivered aerosol lasts 
three times longer than in pMDIs.25 DPIs are often sensitive to 
humidity, which can reduce the delivered dose, while SMIs and 
pMDIs, when left unused for some time, must be re-primed.29 
Advantages and disadvantage of the devices currently avail-
able on the market are summarized in Table 1.
Generally, patients that commit errors during inhala-
tory therapy hiring, tend to be older, more debilitated and 
to have a severe disease. In elderly patients, unintentional 
nonadherence to inhalation therapy often comes from cogni-
tive impairment, hearing or visual loss, and other physical 
disabilities, such as arthritis and tremors resulting in poor 
coordination, which significantly affect their ability to 
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understand and follow the suggested treatment. Complex 
pharmacological regimens are also secondary to multiple 
chronic comorbidities, representing a major risk factor for 
impaired adherence.25
Glycopyrrolate by nebulizer
Taking into account the aging population and the projected 
increase in the prevalence of respiratory tract diseases, 
patients with COPD will become older, and treatment options 
Table 1 Advantages and disadvantages of inhalation devices
Device type Advantages Disadvantages
pMDi – Portable
– Does not require preparation
– No drug contamination risk
– High reproducibility for each actuation
– Multidose
– High number of drugs to choose
– Needs coordination between inspiration and dose actuation
– High oropharyngeal deposition
– Does not always indicate the number of doses left
– Contain propellants
– Need to be re-primed after no use
Ultrafine pMDI – Portable
– Does not require preparation
– No drug contamination risk
– High reproducibility for each actuation
– Multidose
– High lung deposition and minor 
oropharyngeal deposition
– Few drugs to choose
– Needs coordination between inspiration and dose actuation
– Does not always indicate the number of doses left
– Fast expiration if containing formoterol
– Needs to be re-primed after no use
Breath-actuated pMDi – Useful when coordination is lacking
– Useful in older age
– Does not require spacers
– Needs adequate inhalation effort
DPi – No coordination required
– No propellant needed
– Remaining dose counters
– Portable
– Usually multidose
– Short administration time
– Usually requires more steps to prepare the drug prior to inhalation
– Some are single-dose
– Needs adequate inhalation effort
– Higher oropharyngeal deposition
– Usually more expensive than pMDis
– Humidity can reduce the released dose
– Device declivity for a correct loading dose
SMi – easy to use
– Portable
– Multidose
– No propellant needed
– Higher actuation duration limiting the effects 
of poor coordination activation/inhalation
– Needs careful preparation at the first use
– Multiple steps involved
– Needs to be re-primed after no use
Jet nebulizer – easy to use
– No need for coordination
– Adapt for every age (even ,4 years)
– Available for oxygen enrichment
– Contemporaneous use of different drugs
– No propellant needed
– Can be used by bedridden patients
– Cumbersome
– Noisy
– High treatment time
– Possibility of microbial contamination
– Needs cleaning and periodic maintenance
– Needs electricity
– Uncertainty of effective dose delivered to the lung
Ultrasonic wave 
nebulizer
– easy to use Requires minimal cognitive ability
– Lightweight
– Silent
– No need for coordination
– Adapt for every age (even ,4 years)
– Available for oxygen enrichment
– Contemporaneous use of different drugs
– No propellant needed
– Can be used by bedridden patients
– Possible drug heat degradation
– Too much liquid waste
– High treatment time
– Possibility of microbial contamination
– Needs cleaning and periodic maintenance
– Needs electricity
– Uncertainty of effective dose delivered to the lung
Ultrasonic vMT Same advantages as ultrasonic nebulizers
– Shorter treatment time
– High efficiency and less waste
– No drug degradation
– Battery powered
– easy to clean, disinfect and autoclave
– Display delivers feedback during inhalation
– Higher price
– Needs cleaning after every use
– Not available for contemporaneous use of different drugs
– May not readily aerosolize drug suspensions
Abbreviations: DPi, dry powder inhaler; pMDi, pressurized metered dose inhaler; SMi, soft mist inhaler; vMT, vibrating mesh technology.
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that do not require an optimal coordination for activation/
inhalation or require a flow threshold to be activated will 
become the preferable treatment option.
To date, nebulized muscarinic antagonists are limited to 
short-acting formulations (SAMAs), while β-agonists are 
available both as short-acting (SABAs) and as long-acting 
formulations (aformoterol tartrate), the latter approved only 
in the USA. SAMA and SABA, in addition to being the treat-
ment choice in acute conditions, are also often suggested for 
maintenance treatment in selected COPD patients. However, 
to maintain an optimal bronchodilation coverage, three or 
four doses per day are needed when SAMA and SABA are 
delivered via a general purpose jet nebulizer. The latter are 
usually bulky, characterized by limited portability and with 
dispensing times of 10–15 minutes per dose, aspects that 
likely affect patients’ compliance. In view of the aforemen-
tioned limitations, the lack of long-acting molecules that 
would reduce the daily posology and a shorter delivery time 
appear desirable.30
The GOLD document recommends nebulizers to be used 
in specific populations, such as patients with inspiratory 
flow rates as low as ,30 L/s or patients with poor hand-eye 
coordination.1 Furthermore, the benefits of nebulizer treatment 
over DPI and MDI formulations should be evaluated symp-
tomatically and the treatment should be continued as long as 
similar benefits are not achievable by simpler, cheaper, and 
more portable alternatives. Indeed, recent surveys reported 
both patients and their caregivers to be increasingly satisfied 
with nebulized drug delivery, in terms of symptom relief, 
ease to use, and improved quality of life.10,11,31
Nebulizers can convert a liquid into aerosol droplets 
suitable for patient inhalation. Currently, the technologies 
available are mainly represented by air-jet nebulizers, the 
most widely used, and ultrasonic nebulizers. There are 
also two pysicochemical categories of drugs available for 
nebulization: solutions and suspensions. Solutions contain 
a drug dissolved in saline or other liquids. Suspensions 
contain a drug that is not soluble in water or other respi-
rable liquids but exist as a mixture of small drug particles 
suspended in liquid, which jeopardizes their presence in 
each droplet generated during the nebulization process. 
Conventional ultrasonic nebulizers cannot be used to admin-
ister suspensions.30
Due to their safety profile and to a better exacerbation-
preventing effect compared to LABAs,32,33 LAMAs are usu-
ally the preferred starting therapy for COPD patients, but no 
nebulized LAMA is actually available on the market. As a 
part of the maintenance treatment of patients with COPD, 
in last years, glycopyrronium bromide (GB) has been devel-
oped and available as a single agent, in combination with 
LABAs,34–36 or in triple therapy in fixed dose combination 
with LABAs and inhaled corticosteroids (ICSs).37,38 The 
effects of GBn have been studied since 1984 in patients 
affected by asthma and since 1995 in patients with COPD.39,40 
Interestingly, probably due to its limits in administering time 
and portability, nebulization was the first to be studied, but the 
least to be proposed on the market. In the last years, several 
clinical trials have investigated a nebulized formulation of 
GBn delivered by a high efficiency nebulizer, which is cur-
rently awaiting for the US Food and Drug Administration 
(FDA) approval as maintenance therapy in COPD patients.
GBn has been investigated as a soluble molecule named 
EP-101 in 2015.41 Later on, under the name of SUN-101, it 
was part of the Glycopyrrolate for Obstructive Lung Disease 
via Electronic Nebulizer (GOLDEN) development program, 
consisting of a total of seven trials.42–48
GBn was studied to be delivered by the eFlow® Closed 
System (eFlow® CS) device (PARI Pharma GmbH, Starnberg, 
Germany). The latter is characterized by the possibility to 
deliver a wide range of drug volumes (0.5–5 mL) and dosages 
(0.001–1,000 mg). In addition, the hole sizes can be adjusted 
from just ,2 μm upward, allowing this system to deliver 
drugs during consecutive breaths. The eFlow® is a vibrating 
mesh nebulizer, an evolution of 2005 ultrasonic wave 
nebulizers, in which a mesh/membrane with 1,000–7,000 
laser-drilled holes vibrate at the top of the liquid reservoir, 
pressuring out a mist of very fine droplets through the holes. 
The latter technology appears to have solved some important 
issues existent with previous nebulizers, such as having too 
much liquid waste and undesired heating of the medical 
liquid. Portability for these devices is also enhanced by the 
battery-power and lightweight design. A disadvantage of 
vibrating mesh nebulizers consists of the little information 
concerning the ideal dose of the bronchodilator solution 
to be added to the nebulizer; consequently, the potential 
of over-dosing exists if the same dose for conventional jet 
nebulizers is used. To address this concern, a new genera-
tion of closed system mesh nebulizers has been conceived 
that will accept only the ampule containing the specific drug 
approved for use.49
In successive trials, a modified version of the eFlow® 
nebulizer was adopted: the eFlow® CS. The latter is a hand-
held, portable, battery-operated, electronic vibrating mem-
brane nebulizer, modified from an FDA-cleared open-system 
device used to deliver cystic fibrosis medications. Like other 
vibrating mesh nebulizers, the eFlow® is virtually silent, 
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designed to deliver the medication in two to three minutes 
during tidal breathing. It has been shown to improve patient 
compliance due to its comparatively short treatment time 
since it is more efficient than having a vibrating piezoelectric 
element at the bottom of the liquid reservoir (Figure 1).50 
The most common jet nebulizers are usually cumbersome, 
not portable, noisy (up to 60 dB) and require 10–15 minutes 
to deliver the drug.51
Fundamental for the destiny of an aerosolized particle 
is its aerodynamic diameter, determined by geometrical 
diameter, density, and form.52 Only particles with a diameter 
between 5 and 0.5 μm can reach and stay in the lung: 
bigger particles impact on upper airways’ mucosa, while 
smaller ones usually reach alveoli but are also exhaled away 
since they fail to lay on the epithelium.52,53 The mass median 
aerodynamic diameter (MMAD), geometric standard devia-
tion (GSD), and fine particle fraction (FPF, %, ,5 μm) of the 
eFlow® CS system have values independent of formulation 
strength. For both strengths tested, the mean MMAD was 
3.7 μm, the mean GSD was 1.7, and the mean FPF was 72%. 
As expected in tidal breathing conditions, aerosol is expelled 
to waste during the exhalation phase. Compared to general 
purpose nebulizers, which can nebulize different drugs, to 
avoid incorrect dosing of the medication, the eFlow® CS uses 
a unique ready-to-use unit-dose vial, designed to mitigate 
misuse and ensure dose uniformity.3,52,54 The device requires 
to be disassembled and cleaned after each use to prevent 
clogging of the mesh openings. At the time of this review, 
the eFlow® system used for cystic fibrosis is being sold for 
$800–1,000.51
Traditional nebulization route has some limits indeed, 
especially in regard to the output variation between different 
nebulizers of the same type. In fact, factors affecting nebulizer 
output are inextricably linked with those affecting particle 
size and nebulization time.55 Output can be diminished if the 
jet is blocked with dirt or drug crystals. Repeated uses may 
increase the diameter of the air orifice thus increasing the 
mean diameter of the droplets generated and reducing the air 
speed. This aging may be due to mechanical wear from the 
compressed air source or to excessive cleaning. Nebulizers 
designed to deliver small particles may have increased 
residual volume, decreasing drug output and increasing 
recirculation of the nebulizer solution, thus lengthening 
nebulization time. Increasing the volume fill improves drug 
output but lengthens nebulization time. Increasing driving gas 
flow rate may help, but for home use a higher performance 
compressor may be needed.56 Another disadvantage is rep-
resented by the need of the end-user to load the medication 
prior to each administration.57
Despite some drawbacks associated with nebulizers, 
current evidence suggests that the efficacy of treatments 
administered to patients with moderate-to-severe COPD 
via nebulizers is similar to that observed with pMDIs and 
DPIs.20–23 Furthermore, for some patients, the use of both a 
nebulizer as maintenance therapy and a handheld inhaler 
as rescue medication may provide the best combination of 
efficacy and convenience.
Pharmacology of glycopyrrolate 
via nebulizer
Chemistry and pharmacokinetics
Glycopyrronium, the active moiety of its bromide salt, also 
known as glycopyrrolate, is an antimuscarinic drug that was 
initially approved by the FDA for systemic administration 
for the reduction of sialorrhea due to preoperative stages, 
neuromuscular, and drug-related diseases58,59 and due to the 
?????????????????????
????
?????
???????????? ????????
????????
?????????????
??????????
????
?????????????????
Figure 1 Simplified structure of the eFlow® (PARi Pharma GmbH, Starnberg, Germany) nebulizer.
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property of reducing gastric secretions, as a treatment for 
peptic ulcer.60 It is a quaternary ammonium derivative – (1,1-
dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-
2-phenylacetatethat61 – with a peripheral effect similar 
to atropine. The chemical structure of GB is reported in 
Figure 2.
GB is rapidly absorbed into the systemic circulation after 
inhalation, ≈90% via lung and ≈10% via gastrointestinal 
absorption.62 The mean terminal elimination half-life (t
1/2
) 
of GB-DPI, is half that reported for GB-MDI (from 13 to 
22 hours for a dose range of 25–200 μg63 and from 6.3 to 
9.6 hours for a dose range of 14.4–115.2 μg), leaving open 
discussion on whether these pharmacokinetic features should 
be interpreted as a signal favoring the once daily (OD) or a 
bis in die (BID) administration. During the Phase II study 
by Leaker et al,41 a formulation of GBn delivered by the 
eFlow® nebulizer was rapidly absorbed with peak plasma 
concentrations within 15–30 minutes. There were only two 
measurable plasma GBn concentrations available with the 
12.5 μg dose. Therefore, 12.5 μg was not included in the 
dose proportionality analysis. The elimination half-life (t
1/2
) 
of GBn was calculated for the 0–1 and 0–12 hours intervals. 
The median t
1/2
, 0−1 hours ranged from 1.10 to 1.15 hours, 
and median t
1/2
, 0–12 hours ranged from 2.30 to 7.45 hours, 
following administration of 50, 100, 200, and 400 μg of 
GB, respectively.41
Metabolism and elimination
GB is nonenzymatically hydrolyzed to form the major 
circulating metabolite, M9, which is a racemic carboxylic 
acid derivative, formed from the swallowed fraction of 
inhaled GB (Figure 2).62 In animal models, the primary 
biotransformation pathways for GB have been demonstrated 
to include the addition of one or two oxygen atoms to the 
cyclopentane and phenyl rings and dehydrogenation on the 
cyclopentane ring.64 Further hydrolysis of the ester linkage 
forms the M9 metabolite. About 10% of systemic exposure 
is due to the swallowed drug, oral bioavailability of GB 
being 5%. The metabolite M9 has a plasma concentration 
that is approximately the same as that of the parent drug after 
inhalation but not after intravenous administration.64 Biliary 
excretion contributes ~5% to total clearance. GB also forms 
various mono and bis-hydroxylated metabolites in vitro. 
Glucuronide and sulfate conjugates of GB were recovered 
in urine of subjects receiving multiple dosages of inhaled 
drug.64 The most quantitatively important cytochrome that 
contributes to the metabolism of GB is CYP2D6.64
Pharmacodynamics
Muscarinic antagonists promote the relaxation of airway 
smooth muscle by blockade of the acetylcholine receptor.65 
GB is a competitive muscarinic receptor antagonist that bron-
chodilates the airways by inhibiting acetylcholine induced 
bronchoconstriction in bronchial smooth muscle cells.66 
The three main muscarinic receptors related with human 
lung bronchial dynamics are the M
1
, M
2
, and M
3
 receptors. 
M
2
 receptor protects against bronchoconstriction and its block 
may increase heart rate.36,66 The bronchoconstrictor effect of 
acetylcholine is mediated mainly through M
3
 receptors located 
on airway smooth muscle cells, whereas M
1
 receptors enhance 
cholinergic reflexes. In contrast, M
2
 receptors on cholinergic 
nerve endings inhibit acetylcholine release, thus reducing 
bronchoconstriction, and should not be blocked.67 Mucus 
secretion is largely mediated by M
3
 receptors and M
3
 receptor 
blockade may also reduce mucus hypersecretion.68,69 In vitro, 
GB binds with high affinity to all the bronchial muscarinic 
receptors but has four- to fivefold higher selectivity for human 
M
1
 and M
3
 receptors than for the human M
2
 receptor (equilib-
rium binding affinity constants of 9.60–9.81 and 9.47–9.64 
vs 8.70–9.25).6,70 GB has also different dissociation kinetics 
for the three muscarinic receptors, with dissociation half-life 
of 11.4 and 13.9 for M
3
 and M
1
, respectively, vs 1.07 min 
for M
2
 and kinetic off rate of 0.061 and 0.05 vs 0.646 per 
minute, respectively.62,66 GB showed greater equilibrium 
binding selectivity (M
3
 selectivity ratio [ratio of the affinity 
constant for the M
3
 receptor vs that for the M
2
 receptor] of 
7.76-fold vs 2.09-fold) and kinetic selectivity (M
3
 kinetic 
selectivity ratio [ratio of the area under the simulated associa-
tion and dissociation curves for the M
3
 receptor vs that for 
the M
2
 receptor] of 11.41-fold vs 4.30-fold) for M
3
 versus 
M
2
 than tiotropium bromide, indicating the potential for an 
improved therapeutic index.62,66
Selective M
1
 and M
3
 receptors’ blockers such as tiotro-
pium and GB are therefore preferable to nonselective 
OH O
Metabolite M9Glycopyrronium bromide
O
N
CH3
CH3
O
OH
Br –
+ OH
Figure 2 Chemical structure of glycopyrronium bromide (left) and its plasma 
metabolite M9 (right).
Note: M9 is formed through nonenzymatic hydrolysis of glycopyrronium bromide.
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Nebulized glycopyrrolate for COPD
muscarinic antagonists, such as atropine and ipratropium 
bromide, which express their effects also on the M
2
 receptor 
subtype.68,71 Both GB and tiotropium are in fact selective for 
M
1
 and M
3
 receptors and have a similar duration of action 
with slow dissociation for these receptor subtypes.72 The slow 
dissociation profile of GB contributes to the long duration 
of action seen in clinical studies.73 Accordingly, GB rapidly 
dissociates from M
2
 receptors, thus avoiding their prolonged 
presynaptic blockade and reducing the antagonizing effect 
of acetylcholine release.72,74
Compared to tiotropium bromide, GB has a faster onset of 
action both in vitro and in vivo animal models.70 In fact, GB 
has shown to have both lower equilibrium binding affinity 
constants and a faster kinetic off rate (9.59 and 0.061 vs 
10.37 and 0.015 per minute, respectively), which justifies its 
faster onset of action also in patients with moderate-to-severe 
COPD when compared with tiotropium bromide at a dosage 
of 18 μg.75 The onset of action, however, appeared slower 
both in terms of relief from airflow obstruction and in reduc-
tion of static hyperinflation when compared with aclidinium 
bromide 400 μg in a double-blind cross-over study in severe 
and very severe patients with COPD.76
GB has been shown to be more potent than ipratropium 
bromide and tiotropium bromide in terms of concentration 
drug necessary to inhibit the contractile bronchial smooth 
muscle response by 50%.77 In a recent report that compared 
in vivo and in vitro effects of GB-DPI, aclidinium bromide 
DPI, and tiotropium bromide DPI, GB-DPI resulted to be the 
most potent of the three LAMAs investigated, inducing, with 
aclidinium, a faster bronchodilation compared to tiotropium.78 
However, given the fact that so far, the approved marketed 
doses are not isoeffective for the two LAMAs, to make pre-
cise pharmacodynamics speculations of their effect in vivo 
remains a difficult task. A potential disadvantage brought by 
the GB fixed-dose combinations currently available on the 
market is represented by the GB dosage (#50 μg); in fact, 
from the analysis of the forced expiratory volume in the first 
second (FEV
1
) dose–response in pharmacodynamic studies, 
the optimal dose of GB appeared to be at least 100 μg, to be 
reflected in a FEV
1
 difference of .100 mL.11
Glycopyrrolate-approved formulations
GB has been initially approved by the European Medicines 
Agency79 and the Pharmaceuticals and Medical Devices 
Agency80 in 2012 and by the FDA81 in 2015, as a standalone 
treatment for COPD as a dry-powder inhalation formulation. 
Subsequently, while in Europe it has been approved with 
OD posology, FDA approved its usage as BID long-acting 
bronchodilator both as a standalone treatment and as a fixed-
dose DPI combination with indacaterol. An MDI formulation 
containing a fixed-dose combination of GB and formoterol 
fumarate has been available in USA and Japan since 2016. 
A DPI formulation containing a triple combination of GB, 
formoterol fumarate, and beclomethasone has been approved 
for marketing in EU in May 2017.82
At the time of the present review, a nebulized formula-
tion of GB is awaiting approval from FDA as a maintenance 
treatment for patients with COPD.83
Efficacy studies
Phase II and Phase III efficacy and safety clinical trials 
involving GBn are summarized in Table 2.
Phase ii studies
GBn was studied in a Phase II, two-center, randomized, 
placebo-controlled, double-blind, dose ranging, single-dose, 
six-way cross-over trial in 35 patients with moderate-to-
severe COPD (GOLD II/III), aged 40–75 years.41 All patients 
were required to have at least 12% and 150 mL reversibility 
to inhaled ipratropium bromide as inclusion criteria. Eligible 
patients were randomized to receive a single dose of GBn 
via eFlow® nebulizer (12.5, 25, 50, 100, and 200 μg) or pla-
cebo in six treatment visits separated by washout periods of 
5–12 days; each dose was followed by an onset of response on 
placebo-adjusted FEV
1
 in ,5 minutes (60, 80, 100, 130, and 
140 mL). The bronchodilating effect progressively decreased 
over 24 hours period with a dose–response relationship, so 
that the higher the initial dose, the longer the duration of 
bronchodilation. The placebo-adjusted FEV
1
 improvement at 
24 h postdose was .100 mL with both the 100 μg (104 mL 
increase over placebo effect) and 200 μg (118 mL increase) 
doses; only the latter doses produced a significant improve-
ment over placebo.41
The eFlow® was able to deliver all doses of GBn 
in ,2 minutes (range 1.6−1.9 minutes). GBn peak plasma 
concentrations were measured within 15–30 minutes.41
The GOLDEN-1 study was a Phase II, multicenter, 
randomized, double-blind, placebo-controlled, four-period, 
incomplete block, cross-over study.42 The primary outcomes 
were the mean change in 24-hour postdose trough FEV
1
, 
and the standardized change in FEV
1
 area under the curve 
(AUC) (0–12 and 12–24 hours) on days 1 and 7.42 Secondary 
outcome measures were peak FEV
1
 (maximum FEV
1
 during 
the first 4 hours postdose on days 1 and 7); time to onset of 
action (time necessary to obtain a $10% improvement in 
postdose FEV
1
); treatment responders (proportion of subjects 
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with clinically meaningful change from predose in trough 
FEV
1
 on days 1 and 7); and safety and tolerability.42
A total of 140 patients with moderate-to-severe COPD 
were randomized to four of seven treatments: GBn (25, 
50, 100, and 200 μg) or placebo OD via eFlow® nebulizer, 
open-label tiotropium 18 μg OD and open-label ipratropium 
500 μg three times a day delivered via jet nebulizer. All doses 
of GBn demonstrated dose-related and significant improve-
ments in FEV
1
 AUC (0–24 hours) on day 7 compared to 
placebo, with estimated differences between GBn doses and 
placebo ranging between 110 and 169 mL.84
Following the pharmacokinetic profile of GBn, in the 
subsequent Phase II studies, only the BID posology has 
been maintained.
Two randomized, double-blind, placebo- and active- 
controlled Phase II studies, GOLDEN-243,85 and GOLDEN-6,47 
further characterized the efficacy of GBn in terms of dose–
response relationship recruiting a total of 378 patients with 
moderate-to-severe COPD (GOLDEN-2, N=282; GOLD-
EN-6, N=96). The GOLDEN-2 study had a parallel group 
design of 28 days, while the GOLDEN-6 was a 7-day cross-
over trial. It should be underlined that for the GOLDEN-2 
study eligible patients were ,40 years old.47
The primary endpoint of both studies was the change from 
baseline in trough FEV
1
 on day 7 or day 28. Safety and toler-
ability were evaluated based on the incidence of treatment-
emergent adverse events (TEAEs), serious AEs (SAEs), 
and discontinuations due to TEAEs. FEV
1
 AUC 0–12 was 
a secondary endpoint. The data were pooled for the lung 
function assessments, common to both studies.31,47
In both studies, increasing doses of GBn (3–100 μg 
BID via eFlow® CS nebulizer) were compared with placebo 
or aclidinium bromide 400 μg BID (Tudorza® Pressair®). 
GBn produced rapid onset (#5 minutes) dose-related 
bronchodilation following a single-dose administration. 
Improvements were maintained over a 24-hour period at all 
doses .50 μg.41,47 The primary endpoints of both studies were 
reached obtaining on days 7 and 28 a significant improve-
ment of the placebo-adjusted trough FEV
1
, with dose-related 
improvements ranging from 82 mL for the 6.25 μg dose to 
177 mL for 100 μg BID, with corresponding changes in FEV
1
 
AUC
0–12
, ranging from 84 to 183 mL. The improvements in 
lung function for the 25 and 50 μg BID doses were com-
parable to those obtained with aclidinium bromide (trough 
FEV
1
 =157 mL, FEV
1
 AUC
0–12
 =190 mL). The GBn dose of 
3 μg BID was identified as the “no-effect” dose.43,46,86
The GOLDEN-2 and GOLDEN-6 dose-finding studies 
supported the selection of GBn 25 and 50 μg BID doses to 
advance in the subsequent Phase III GOLDEN trials.43,45,86
Phase iii studies
GOLDEN-344 and GOLDEN-445 were twin Phase III, 12 weeks, 
randomized, double-blind, placebo-controlled, parallel-
group, multicenter, efficacy, and safety trials.
The primary endpoint was change from baseline at week 
12 in trough FEV
1
. Key secondary endpoints included forced 
vital capacity (FVC), St George’s Respiratory Questionnaire 
(SGRQ), and rescue medication use. Safety was also assessed 
throughout the study.
Included patients were 40–75 years old, with a $10 pack-
year smoking history and a moderate-to-very-severe COPD 
(postbronchodilator FEV
1
 ,80% of predicted normal or FEV
1
/
FVC ratio ,0.70). To include a closer-to-real-life COPD popu-
lation, patients with maintenance treatment with LABA (31%) 
and ICS (29%) and co-existing cardiovascular disease were 
not excluded in both studies; patients were stratified by cardio-
vascular history, 64% being at high risk.87 The administration 
of both doses of GBn/eFlow® (25 and 50 μg BID) resulted 
in statistically and clinically significant improvements com-
pared to baseline in placebo-adjusted trough FEV
1
 (GOLD-
EN-3: +105 and +126 mL; P#0.0001; GOLDEN-4: +84 
and +82 mL; P#0.0001) and placebo-adjusted trough FVC 
(GOLDEN-3: +149 and +167 mL, P,0.001; GOLD-
EN-4: +130 and +113 mL, P,0.01) at week 12.87,88
GOLDEN-5 study was a Phase III, randomized, open-
label, active-controlled, parallel-group, multicenter, long-
term safety trial of 48 weeks of treatment with GBn delivered 
by the eFlow® CS system or tiotropium 18 μg OD in 1,087 
moderate-to-very-severe COPD patients.46 The population 
included patients with background use of LABA and history 
of significant cardiovascular disease.46
The primary endpoints were the incidence of TEAEs, 
SAEs, and discontinuations due to TEAEs. Secondary 
endpoints included patient-reported outcomes, rescue medi-
cation use, and the mean change from baseline over 48 weeks 
in trough FEV
1
. Lung function results confirmed the findings 
from GOLDEN-3 and -4 studies. Considering patients with 
and without background LABA therapy, improvements in 
trough FEV
1
 after GBn administration were not different, 
99 and 105 mL, respectively.46,89
GOLDEN-7 is a Phase I randomized, open-label, single-
dose per dosing period, five-way cross-over study in subjects 
aged 40–70 years with a diagnosis of moderate-to-severe 
COPD designed to evaluate the total systemic exposure and 
lung bioavailability of GBn compared to GB delivered by 
Breezhaler® (Seebri®). GB was administered with and with-
out activated charcoal. Unfortunately to date, no results are 
available for this study, as the available abstracts have been 
withdrawn.47,90
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Safety and tolerability
During the Phase II trial conducted by Leaker et al, single 
doses of GBn were well tolerated with AE profiles compa-
rable to placebo. After all dosages, there were no clinically 
relevant changes in vital signs and ECG parameters, includ-
ing QTc, and no typical muscarinic side effects, such as dry 
mouth and increased heart rate.41
In the GOLDEN-1, all doses of GBn were well tolerated 
with similar AE rates between placebo and GBn (31.2, 29.7, 
26.9, 35.5, and 30.7% for placebo, 25, 50, 100, and 200 μg, 
respectively). There was no apparent dose–response relation-
ship for incidence and severity of AEs. Mean changes in 
vital signs and ECG parameters from baseline to day 7 were 
comparable between the treatment groups.41 No clinically 
significant differences compared to placebo were observed 
in terms of heart rate, blood pressure, and ECG parameters.42 
The GBn safety profile was similar to placebo, tiotropium, 
and ipratropium in regard to cardiovascular AEs.91
GBn was well tolerated in GOLDEN-3 and -4 trials, 
with a combined overall incidence of TEAEs being numeri-
cally lower with GBn 25 and 50 μg BID doses compared to 
placebo (43.4, 50.7, and 52.3% for GBn 25 and 50 μg doses 
and placebo, respectively). The most frequent AEs were 
represented by skin injury, headache, acute COPD exacerba-
tions, cough, and dyspnea. Discontinuations due to TEAEs 
were numerically higher in the placebo group. There was one 
cardiovascular-related death in the 50 μg BID group.88
A safety analysis of the 48 week GOLDEN-5 trial, in 
which the primary objectives were the number and percent-
age of patients with TEAE, demonstrated comparable and 
consistent results with GOLDEN-3 and GOLDEN-4 trials 
at 12 weeks.46,89 Discontinuation rate was 10% for GBn and 
2.8% in patients receiving tiotropium; the most frequent 
TEAEs leading to discontinuation for GBn were cough 
(2.3%), dyspnea (1.5%), and COPD (1.9%). The incidence 
rate of major adverse cardiovascular events (MACE) was 6.4 
per thousand person-years for GBn and 20.3 for tiotropium.89 
There were seven deaths during the study, none of which were 
considered treatment related: three in the GBn group (0.5%) 
and four in the tiotropium group (0.9%).89 Results from 
GOLDEN-5 trial, focused on long-term safety of GBn com-
pared to placebo, showed that GBn BID was well tolerated, 
with a similar overall incidence of adverse events compared 
to the standard of care (48.6% for patients treated with GBn 
and 51.2% for tiotropium).89 Compared to tiotropium, the 
incidence of MACE was lower in the GBn group, although 
not significantly different compared to patients treated 
with tiotropium (6.4/1,000 persons per year for GBn and 
20.3/1,000 per year for tiotropium), finding consistent with 
results from the GOLDEN-2 trial.85 The pooled analysis of 
GOLDEN-3 and -4 trials demonstrated a very low incidence 
of anticholinergic-related events such as dry mouth, with an 
incidence ranging between 0.5 and 2.3% in patients treated 
with GBn; only one gastrointestinal obstruction was reported 
in both studies, while glaucoma-related adverse events were 
very rarely observed (0.5 and 0.2% for GBn 25 and 50 μg 
doses, respectively).88 As for urinary tract adverse events, 
urinary tract infection was reported in 2.3 and 1.9% for the 
GBn 25 μg dose and 3.2 and 2.3% for the highest dose across 
the GOLDEN-3 and -4 trials, respectively. Urinary retention 
was not observed throughout the studies.
Quality of life, patient satisfaction, 
and acceptability
Pooled data including respiratory symptoms from GOLDEN-3 
and -4 studies (1,293 patients in total) and data from the 
long-term trial GOLDEN-5 (1,086 patients) were analyzed. 
Patients had the same inclusion criteria across all trials.87–89
Clinically meaningful changes (#4.0 unit reduction) 
in SGRQ scores at week 12 were observed in 46.8, 41.7, 
and 34.5% of patients treated with GBn 25 and 50 μg BID 
dosages and placebo, respectively. Improvements were 
largely driven by changes in the SGRQ symptom domain.87 
During GOLDEN-5, administration of GBn 25 and 50 μg 
BID resulted in statistically significant improvements from 
baseline in health-related quality of life, using the Evalu-
ating Respiratory Symptoms in COPD (E-RS™: COPD) 
electronic diary. E-RS™: COPD total score was collected 
starting from week 2 (P,0.05 vs placebo for both doses), 
with no significant effect on rescue medication use. E-RS 
responders at week 12 were 48.1, 40.3, and 36.9% of patients 
in the GBn 25 μg, 50 μg, and placebo groups, respectively; 
the placebo group scored −0.6 from the baseline while 
GBn −1.76 and −1.52 for doses of 25 and 50 μg, respec-
tively. In GOLDEN-5, improvements in E-RS total scores 
were seen across all visits in the GBn and tiotropium groups, 
with similar changes in the score (from −1.30 to −1.86 on 
the baseline score at week 12 and −1.5 for both tiotropium 
and GBn at week 48).92
A survey conducted among patients participating in the 
GOLDEN-5 study, which collected 473 questionnaires about 
patient-reported satisfaction with the investigational nebu-
lizer and the ability to use it, suggested that regardless of pre-
vious nebulizer use, 75% of patients were “satisfied” or “very 
satisfied” with the novel delivery system. A total of 83% of 
patients also reported being “confident” to “very confident” 
that the study drug was being efficiently delivered to their 
lungs by the eFlow® CS nebulizer. Additionally, .70% of 
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the patients also rated the investigational nebulizer as “easy” 
or “very easy” to assemble, operate and clean.93
Conclusion and place in therapy
The number of elderly patients with COPD will increase 
as we become more efficient treating the disease and their 
chronic morbidities. It is not uncommon during everyday 
clinical practice to be unable to prescribe an adequate inhala-
tion therapy for an elderly COPD patient due to his inability 
to handle the device or his low adherence to the suggested 
treatment. Treatment options that do not require coordination 
for activation and inhalation or necessitate an inspiratory 
peak flow threshold to be activated should represent the best 
treatment option for these patients. Nebulizers seem to fulfill 
that missing spot, although no nebulized bronchodilators 
are currently available for the treatment of stable COPD. 
The use of high efficiency nebulizers may bring together 
the highest number of advantages and the lowest number of 
disadvantages in terms of treatment efficacy and tolerability. 
GBn might be the first nebulized LAMA to be approved for 
use in COPD patients. The eFlow® CS nebulizer has also 
some limits that should be considered: it is expensive and its 
maintenance may be complicated due to the need of cleaning 
the device after each administration. The latter aspect should 
not be forgotten, especially in patients that may be a priori 
selected for their inability to handle properly traditional 
inhalation devices.
The pathophysiology and functional impairment in 
patients with COPD guides the current technology dedi-
cated to bronchodilator delivery, which should strive to 
assure the best efficiency of drug deposition within the 
lung, obtained with the lowest chance of critical errors pos-
sible. Nebulized glycopyrronium may represent the starting 
point of an alternative tool to increase the efficiency of long 
term bronchodilator therapy, especially in patients who 
present issues with the employment of devices containing 
predosed drugs.
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